Triaj Inc.

Revolutionizing the diagnosis, treatment, and care of patients


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9



Triaj: Fast Facts

Medical errors are the #3 cause of death in the United States.

Martin Eichelberger, MD founded Triaj in 2018 to create a powerful Clinical Decision Support System, which provides best practice patient treatment that is available anywhere, anytime as a cloud-based mobile communications network solution.

Major Problem

The One True Solution

Triaj addresses this problem by providing the following Value Propositions:

Expert Medical Knowledge +
Cloud-Based App

The Triaj SaaS solution and App, consists of world expert, best-practice methods for the healthcare provider team, accessible as a cloud-based application on an Internet-enabled handheld device.

Designed to enhance team communication and collaboration, the Triaj solution employs easy-to-use Checklists, Procedures, and Resources, with rapid access to vital patient and best practices information at the bedside.

The initial Triaj product release focuses upon Pediatric Trauma Care (founder expertise).

 

The construction of the network and mobile application architecture provides an infrastructure that can be duplicated and scaled to expand best practice networking to include the treatment of other medical conditions for patients of all ages

Quick access to vital medical knowledge anywhere, at any time, after an injury to the patient, will reduce the chance of death and disability while decreasing the cost of care.

The Triaj platform is an enterprise solution for multiple hospital networks, and an individual educational and informational platform distributed via the Apple App store.

Why We’ll Lead

Our Triaj-led revolution will build a successful business with high shareholder ROI.

We are in a strong market position for 2023 with a TAM of $19.4 billion, SAM of $1.2 billion and a SOM of $46.4 million. We are also confident we can achieve recurring subscription revenue of $46.4 million in 2023.

Further, we have an extraordinary EBITDA of $17.5 million and 38% in 2023. And we'll achieve this success with a total equity investment of only $7,000,000 - $9,500,000 million until positive income is achieved in 2022.

Traction & Accomplishments

Completed MVP of initial product release, having Beta Tested with 450+ clinical professionals, with an average positive rating of 85%

We released the individual application on 9/15 in the app store and have already secured numerous recurring subscriptions 

We are also piloting the SaaS Enterprise solution with three hospitals, who we hope to contract before the end of 2020

Working with our Legal/IP Partner Wilson Sonsini we filed an extensive Provisional Patent Application (PPA) on 10/14/19.  It contains 72 individual patent claims regarding Triaj IP.  We updated the original PPA with additional concepts and claims on 9.14.20

We believe that our IP position is extremely strong

IP + Strategic Partners

Intellectual Property Protection

  • The Triaj Cloud-based Algorithm Architecture is Protected
  • Patent Protection Application Complete: 72 Pending Approvals for Innovative Technology
  • Triaj has exclusive ownership of IP (Trademark and Copyright)
  • Content Management: Best practices medical knowledge with cloud security to certify users prior to download as an added IP protection
  • Artificial Intelligence (AI): Machine Learning (AI) will provide a network of evolving best practices via real time access to actual diagnosis and treatment results

Meet The Team

Martin R. Eichelberger, M.D., FACS, FAAP
Founder, President and CEO

  • Chief Surgeon and Founder of Emergency Trauma and Burn Services at Children’s National Health System
  • Co-Founder: Safe Kids Worldwide
  • Global Non-Profit focusing on reducing childhood death rate from injury
  • 400 Coalitions in 34 countries
  • Medical Faculty at George Washington University
  • Education: Hahnemann University School of Medicine, BA Princeton University

Dave Martin
Executive Chairman

  • Managing Partner 280Capital Partners
  • Silicon Valley Technology Company Leader (Systems, Storage, Software)
  • CEO-in-Residence at Warburg Pincus
  • Executive: IBM, Intersil, National Semiconductor
  • Education: BSE Princeton University

Jane Ball, R.N., DrPH
Chief Nursing & Content Officer

  • Founder and Managing Director, Emergency Medical Services at Children’s National Health System
  • Consultant, American College of Surgeons Committee on Trauma
  • Education: DrPH and MPH, Johns Hopkins University, Bloomberg School of Public Health, Johns Hopkins Hospital School of Nursing

Todd B. Eichelberger
VP Sales & Marketing

  • Founder & President, Global Sports Enterprise
  • Global Sr Sales Director, Nixon Inc.
  • Sales Director, Adidas Group
  • Education: BA, Princeton University; M.I.T. Artificial Intelligence: Applications in Business Strategy

Rick Gehringer
Business Advisor

  • CIO Milken Institute
  • CIO Brookings Institution and Westfield Group
  • Software Business Unit Executive at Trimble
  • Education: Johns Hopkins University Carey Business School, BS Business Admin Cal State University Long Beach

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.